Can Obama Help Vete...
Health Care: Drugs
AstraZeneca PLC (AZN: NYSE)
$40.08 -0.33 | -0.82%
06/01/12 - 04:01 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 33.59B | 33.27B | 32.80B | 31.60B |
| Cost of Sales | 3.48B | 3.65B | 3.69B | 3.98B |
| Gross Operating Profit | 30.12B | 29.62B | 29.12B | 27.62B |
| Selling, General, and Administrative Expenses | 11.51B | 10.78B | 11.63B | 11.20B |
| Research & Development | 5.52B | 5.32B | 4.41B | 5.18B |
| Operating Income before D & A (EBITDA) | 13.08B | 13.52B | 13.08B | 11.24B |
| Depreciation & Amortization | 2.55B | 2.74B | 2.09B | 2.62B |
| Interest Income | 552.00M | 516.00M | 462.00M | 142.00M |
| Other Income - Net | 0.00 | 712.00M | 553.00M | 1.22B |
| Special Income / Charges | 2.26B | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | 13.35B | 12.01B | 12.00B | 9.98B |
| Interest Expense | 980.00M | 1.03B | 1.20B | 1.30B |
| Pre-Tax Income | 12.37B | 10.98B | 10.81B | 8.68B |
| Income Taxes | 2.35B | 2.90B | 3.26B | 2.55B |
| Minority Interest | 33.00M | 28.00M | 23.00M | 29.00M |
| Net Income From Continuing Operations | 9.98B | 8.05B | 7.52B | 6.10B |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | 9.98B | 8.05B | 7.52B | 6.10B |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | 9.98B | 8.05B | 7.52B | 6.10B |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
7.72B | 8.05B | 7.52B | 6.10B |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | 9.98B | 8.05B | 7.52B | 6.10B |
| Basic EPS from Continuing Ops. | 7.33 | 5.60 | 5.19 | 4.20 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | 7.33 | 5.60 | 5.19 | 4.20 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | 7.33 | 5.60 | 5.19 | 4.20 |
| Basic Normalized Net Income/Share | 5.67 | 5.60 | 5.19 | 4.20 |
| EPS fr Continuing Ops. | 7.30 | 5.57 | 5.19 | 4.20 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | 7.30 | 5.57 | 5.19 | 4.20 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | 7.30 | 5.57 | 5.19 | 4.20 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
5.65 | 5.57 | 5.19 | 4.20 |
| Dividends Paid per Share | 2.70 | 2.41 | 2.09 | 1.90 |
Portfolios with AZN
- Portfolio NameUser Type
- UserGFNN Stockdiagnostics 14
- UserThe Coming M&A boom
- ContributorHighest-Yielding Drug Stocks
- Contributor10 Dividend Stocks Still Pa...
- User2012 performers
- Contributor6 European Stocks Resistant...
- UserMoney Maker
- Userkeithj
- ContributorRocket Stocks for the Week ...
- ProJohn Hussman
Latest AZN Headlines from TheStreet
- 9 High-Yield Stocks to Consider in Lieu of Bonds 06.01.12 | 01:06 pm
- AstraZeneca PLC (AZN): Today's Featured Health Care Winner 05.03.12 | 05:05 pm
- The Next Big Thing in Biotech: M&A
04.27.12 | 05:04 am - AstraZeneca PLC (AZN): Today's Featured Drugs Loser 04.26.12 | 05:04 pm
- Rupert Murdoch in Second Day of Testimony: Hot Trends 04.26.12 | 08:04 am
- 14 Deal-Ready Stocks for the M&A Boom 04.26.12 | 06:04 am
- AstraZeneca Buys Ardea Biosciences for $1.26 Billion: Hot Trends 04.23.12 | 10:04 am
- AstraZeneca Buys Ardea Biosciences for $1.26B: Hot Trends 04.23.12 | 08:04 am
- AstraZeneca Wins Patent Protection on Seroquel: Hot Trends 03.30.12 | 10:03 am
- Stocks to Watch: Research In Motion, Dunkin' Brands (Update 1) 03.30.12 | 08:03 am
Press Releases for AZN
- Data Presented At The European Atherosclerosis Society Congress Reinforces The Differentiating Benefits Of CRESTOR[TM] In Comparison To Atorvastatin And Simvastatin - PR Newswire 05.28.12 | 01:05 am
- SYMBICORT® (budesonide/formoterol Fumarate Dihydrate) Long-Term Study Shows Similar Safety Profile When Compared To Budesonide Monotherapy In African-American Patients With Asthma - Business Wire 05.10.12 | 09:05 am
- LUNAR Examines Cholesterol-Lowering Effects Of CRESTOR® (rosuvastatin Calcium) Compared With Atorvastatin In Patients With Acute Coronary Syndrome - Business Wire 05.01.12 | 09:05 am
- AstraZeneca And The Medicines Company Announce Global Collaboration In Acute Ischemic Heart Disease - Business Wire 04.25.12 | 12:04 pm
- AstraZeneca Launches DUTOPROL™ (metoprolol Succinate Extended Release/hydrochlorothiazide) Tablets For High Blood Pressure In U.S. - Business Wire 04.12.12 | 09:04 am
- US District Court Finds SEROQUEL XR Formulation Patent Valid And Infringed - Business Wire 03.29.12 | 05:03 pm
- Crestor Delivers Latest LDL-C Targets In High-Risk Patients At Lower Doses Than Other Statins - PR Newswire 03.26.12 | 01:03 pm
- US Court Denies Preliminary Injunction Application Against The FDA And Dismisses AstraZeneca’s Lawsuit Without Prejudice - Business Wire 03.26.12 | 02:03 am
- New Data Suggests Results Of PLATO Genetic Sub-Study Outcomes For BRILINTA® (Ticagrelor) Not Driven By Poor Metabolizers Of Clopidogrel - Business Wire 03.25.12 | 11:03 am
- New Data Suggests BRILINTA® (ticagrelor) Reduced First And Recurrent Cardiovascular And Ischemic Events - Business Wire 03.25.12 | 11:03 am
Partner Headlines for AZN
- Healthcare Biz Recap: Aeterna Zentaris Shares Surge, J&J Files with FDA - Wall St. Cheat Sheet 05.31.12 | 10:05 am
- Analyst Insights: Finish Line, BioMarin Pharma, Laboratory Corp, Ocz Technology, AstraZeneca May 31st - Wall St. Cheat Sheet 05.31.12 | 10:05 am
- 6 FTSE100 6%+ Dividend Yielders - Seeking Alpha 05.20.12 | 08:05 am
- Merger Arbitrage Mondays - May 14, 2012 - Seeking Alpha 05.14.12 | 09:05 am
- 4 New Reasons To Be Bullish On Sanofi Now - Seeking Alpha 05.13.12 | 09:05 am
- This Developmental Pharma Has Potential To Be A Long Term Multibagger - Seeking Alpha 05.03.12 | 09:05 am
- Spectrum: Increased Fusilev Production May Boost Stock - Seeking Alpha 04.30.12 | 09:04 am
- Benzinga's M&A Chatter for Friday April 27, 2012 - Benzinga 04.28.12 | 08:04 pm
- Earnings Recap for April 26, 2012 - Benzinga 04.26.12 | 09:04 am
- Amgen Beats but Maintains Outlook - Analyst Blog - Zacks 04.25.12 | 10:04 am
